Group 1 - The company will hold its first extraordinary general meeting of shareholders in 2025 on July 7 at 9:30 AM in Beijing [1][3] - The voting will be conducted through a combination of on-site and online voting systems provided by the Shanghai Stock Exchange [3][4] - The registration for attending the meeting will be open from June 30 to July 2, 2025, and shareholders must present identification and relevant documents [6][5] Group 2 - The meeting will review proposals that have already been approved by the company's board of directors [2][3] - Shareholders can vote through the Shanghai Stock Exchange's online voting system, with specific time slots for voting on the day of the meeting [1][4] - Shareholders holding multiple accounts can aggregate their voting rights across all accounts for the same category of shares [5][4]

证券代码：600511 证券简称：国药股份 公告编号：临 2025-017 国药集团药业股份有限公司 特此公告。 | 姓名 | 离任职务 | 离任时 | 原定任期 | | 离任原因 | 是否继续 在上市公 司及其控 | 具体职务 | 是否存在 未履行完 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 间 | 到期日 | | | 股子公司 | （如适用） | 毕的公开 | | | | | | | | | | 承诺 | | | | | | | | 任职 | | | | 蒋昕 | 董事、战略委员 | 2025年6 | 2025 | 年 4 | 退休 | 否 | / | 否 | (一) 提前离任的基本情况 | | 会委员（召集 | 月 | 20 日 | 月 7 | 日 | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 人）、提名委员 | | | | | | | | | | | | 会委员 | | | | | | | | | ...

证券代码：600511 证券简称：国药股份 公告编号：2025-019 股东大会召开日期：2025年7月7日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 (一)股东大会类型和届次 2025年第一次临时股东大会 (二)股东大会召集人：董事会 (三)投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结合的 方式 国药集团药业股份有限公司 关于召开2025年第一次临时股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (四)现场会议召开的日期、时间和地点 召开的日期时间：2025 年 7 月 7 日 9 点 30 分 召开地点：北京市东城区永定门西滨河路 8 号院 7 楼中海地产广场西塔 8 层 会议室 (五)网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2025 年 7 月 7 日 至2025 年 7 月 7 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东 ...

证券代码：600511 证券简称：国药股份 公告编号：临 2025-018 国药集团药业股份有限公司 第八届董事会第二十五次会议决议公告 该议案尚需提交公司 2025 年第一次临时股东大会审议。 本公司董事会及全体董事保证本公告内容不存在任何虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性 和完整性承担法律责任。 一、 董事会会议召开情况 国药集团药业股份有限公司（以下简称"公司"或"国药股 份"）第八届董事会第二十五次会议通知及资料于 2025 年 6 月 16 日以书面、电子邮件等形式发出，会议于 2025 年 6 月 20 日 以现场结合通讯表决方式在北京召开。本次会议应到董事五名， 实到董事五名，其中四名独立董事参加了会议，全体董事共同推 举董事余兴喜先生主持本次会议，监事和部分高管列席会议，符 合《公司法》和《公司章程》的有关规定。 二、 董事会会议审议情况 本次会议审议并通过了如下决议： （一）以 5 票同意、0 票反对和 0 票弃权的结果审议通过《关 于提名董事候选人的议案》。 公司董事会提名刘月涛先生（简历见附件）、周滨先生（简 1 历见附件）为公司第八届董事会董事候选人，任期自 ...

Group 1 - The core index of the China Securities Index for Food and Major Consumer Goods Retail has shown a decline of 2.40% over the past month, 6.58% over the past three months, and 6.48% year-to-date [1] - The index is composed of listed companies in the food and drug retail sector, reflecting the overall performance of these companies, with a base date of December 31, 2004, set at 1000.0 points [1] - The top ten weighted companies in the index include Yonghui Supermarket (6.61%), Digital China (6.21%), Wancheng Group (4.68%), Shanghai Pharmaceuticals (4.41%), Yifeng Pharmacy (4.32%), Jiuzhoutong (3.86%), Kidswant (3.41%), Sinopharm (3.25%), Wangfujing (3.17%), and TianKang (3.09%) [1] Group 2 - The market segments represented in the index include 43.94% in pharmaceutical commerce, 21.32% in supermarkets and convenience stores, 20.29% in specialty retail, and 14.46% in department stores [2] - The index samples are adjusted biannually, with adjustments occurring on the next trading day after the second Friday of June and December each year [2] - In special circumstances, the index may undergo temporary adjustments, such as when a sample company is delisted or undergoes mergers, acquisitions, or splits [2]

南方财经全媒体记者林汉垚 北京报道 近日，多款创新药密集上市，创新药板块关注度持续提升。中邮证券研报指出，创新药板块近期具备较 多催化，海外BD、ASCO大会等事件持续提高板块热度。国内创新药企迎来估值重塑，有望成为贯穿 全年的投资主线。 在此背景下，保险资金作为"长期资金"也将目光投向生物医药、创新药领域，21世纪经济报道记者通过 Wind统计，今年以来，险资共调研医疗健康领域上市公司112家，其中西药行业上市公司50家。 业内人士表示，随着中国医疗健康产业的蓬勃发展，保险资金正以其长期性和稳定性，成为推动创新药 研发的重要力量。 创新药板块强势增长 据了解，上海医药是沪港两地上市的大型医药公司，在医药商业与医药工业板块均处于国内领先地位。 上海医药工业板块覆盖全面，在生物药、化药、中药和罕见病药物等领域积极开展创新转型。其中，中 随着人口老龄化程度的加深、恶性肿瘤和慢性疾病的增加，以及居民健康意识的提高，民众对创新药和 医疗健康管理服务的需求也逐步增强。 2024年7月5日,国务院召开国务院常务会议审议通过《全链条支持创新药发展实施方案》，会议指出， 发展创新药关系医药产业发展，关系人民健康福祉。要全链条 ...

Core Viewpoint - The article emphasizes the importance of oral hygiene and presents a new oral antibacterial paste, Jilikang®, developed by China National Pharmaceutical Group, which claims to effectively eliminate oral bacteria and maintain oral health. Group 1: Product Features - Jilikang® is classified as a second-class disinfectant product, certified by the state, distinguishing it from most market toothpaste which are cosmetic products [9][10] - The antibacterial rate against common bacteria such as E. coli and Staphylococcus aureus exceeds 80% [11] - The product contains lysozyme, which is described as a "guardian of the oral cavity," capable of penetrating all corners of the mouth for comprehensive cleaning [24][26] Group 2: Efficacy and Testing - The antibacterial rate against Helicobacter pylori is reported to be over 99% [13][28] - Testing results show that the product achieves an antibacterial rate of 95.6% against E. coli after 20 minutes of application [12] - The product has been tested and meets the standards set by GB15979, ensuring its safety and efficacy [39] Group 3: Market Position and Pricing - The product is positioned as a premium oral care solution, with a promotional price of 59 yuan for three tubes, significantly lower than the regular price of 117 yuan [17] - The article highlights that less than 5% of toothpaste on the market is classified as disinfectant products, indicating a unique market position for Jilikang® [36] Group 4: Brand and Company Background - China National Pharmaceutical Group is noted for its comprehensive strength in the pharmaceutical industry, with a strong research and development team [22] - The company’s products are produced in a sterile environment, ensuring high quality and safety standards [36][38]

Core Viewpoint - The article emphasizes the importance of oral hygiene and presents a new oral antibacterial paste, Jilikan, developed by China National Pharmaceutical Group, which claims to effectively eliminate oral bacteria and maintain oral health. Group 1: Product Introduction - Jilikan oral antibacterial paste is a disinfectant product certified as a Class II disinfectant by the state, distinguishing it from most market toothpaste that are merely cosmetic products [11][13][15]. - The product has a high antibacterial rate of over 80% against common bacteria such as E. coli and Staphylococcus aureus [16][18]. - It is reported that the paste can achieve an antibacterial rate of over 99% against Helicobacter pylori, a highly infectious bacterium [18][32]. Group 2: Market Positioning - The article highlights that less than 5% of toothpaste on the market are disinfectant products, making Jilikan a rare offering in this category [41][43]. - The product is manufactured in a sterile environment, ensuring high quality and safety standards [43][45]. Group 3: Consumer Benefits - Jilikan is designed to provide long-lasting fresh breath and maintain a healthy oral environment, which is particularly beneficial for social interactions [20][35]. - The paste is described as having a pleasant texture and aroma, enhancing the overall brushing experience [48][50][52].

截至2025年6月13日收盘，国药股份（600511）报收于30.34元，较上周的30.51元下跌0.56%。本周，国 药股份6月10日盘中最高价报31.55元。6月13日盘中最低价报30.34元。国药股份当前最新总市值228.92 亿元，在医药商业板块市值排名4/31，在两市A股市值排名670/5150。 本周关注点 公司公告汇总：国药股份2024年年度权益分派实施，每股现金红利0.80元（含税） 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 A股每股现金红利0.80元（含税） 股权登记日：2025年6月17日 除权（息）日和现金红利发放日：2025年6月18日 差异化分红送转：否 分配方案：以方案实施前的公司总股本754502998股为基数，每股派发现金红利0.80元（含税）， 共计派发现金红利603602398.40元(含税） 分配实施办法：无限售条件流通股的红利委托中国结算上海分公司派发，控股股东国药控股股份 有限公司的现金红利由本公司直接发放 扣税说明： 对于个人股东及证券投资基金，持股期限超过1年的，股息红利所得暂免征 ...

Group 1 - A-shares market experienced a pullback on June 13, with the Shanghai Composite Index closing at 3377 points, down 0.75% [1] - A500 Index ETF (159351) also declined by 0.62%, with a premium rate of 0.14% [1] - The A500 Index ETF recorded a total trading volume of 3.012 billion yuan, ranking first among similar products in the market, with a turnover rate of 20.82% [1] - Strong performance was noted in sectors such as military, shipping, and gold, with notable stocks like AVIC Chengfei rising by 11% and COSCO Shipping Energy, Aerospace Rainbow, and China Merchants Energy increasing by over 6% [1] - The mid-term adjustment of the CSI A500 Index sample stocks took effect on June 13, adding 21 new stocks including Hunan Gold and Bai Li Tianheng [1] Group 2 - A500 Index ETF (159351) tracks the CSI A500 Index, consisting of 500 large-cap and liquid stocks across various industries, providing a balanced exposure to mid and large-cap styles [2] - The ETF includes a high proportion of new productivity components, making it a useful tool for investors to allocate to representative A-share companies [2] - Investors can also access quality core asset opportunities through the A500 Index ETF linked funds (Class A 022453; Class C 022454) [2]